Prognostic role of diabetes mellitus in hepatocellular carcinoma patients after curative treatments: A meta-analysis

Hepatobiliary and Pancreatic Diseases International

Volumn 10, Issue 4, 2011, Pages 346-355

  Wang, Wei Min ^a   Xu, Yang ^a   Yang, Xin Rong ^a   Wang, Yao Hui ^b   Sun, Hai Xiang ^a   Fan, Jia ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

Diabetes mellitus; Hepatocellular carcinoma; Meta analysis; Prognostic factors; Survival

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER THERAPY; COCHRANE LIBRARY; DATA BASE; DIABETES MELLITUS; EMBASE; HIGH RISK BEHAVIOR; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; PROGNOSIS; SURVIVAL TIME;

EID: 79961200831     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(11)60059-3     Document Type: Article

References (64)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J Hepatol 2003;38:S136-149.
3. Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:187-196.
4. Strickler HD, Wylie-Rosett J, Rohan T, Hoover DR, Smoller S, Burk RD, et al. The relation of type 2 diabetes and cancer. Diabetes Technol Ther 2001;3:263-274.
5. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006;43:1295-1302.
6. Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000;92:1096-1099.
7. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-468.
8. Gao C, Yao SK. Diabetes mellitus: a true independent risk factor for hepatocellular carcinoma? Hepatobiliary Pancreat Dis Int 2009;8:465-473.
9. Huo TI, Hsu CY, Huang YH, Hsia CY, Lin HC, Lee PC, et al. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int 2010;30:198-207.
10. Amarapurkar DN, Patel ND, Kamani PM. Impact of diabetes mellitus on outcome of HCC. Ann Hepatol 2008;7:148-151.
11. Komura T, Mizukoshi E, Kita Y, Sakurai M, Takata Y, Arai K, et al. Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treatment in patients with viral hepatitis. Am J Gastroenterol 2007;102:1939-1946.
12. Kawamura Y, Ikeda K, Arase Y, Yatsuji H, Sezaki H, Hosaka T, et al. Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis. J Gastroenterol Hepatol 2008;23:1739-1746.
13. Huo TI, Wu JC, Lui WY, Huang YH, Lee PC, Chiang JH, et al. Differential mechanism and prognostic impact of diabetes mellitus on patients with hepatocellular carcinoma undergoing surgical and nonsurgical treatment. Am J Gastroenterol 2004; 99:1479-1487.
14. Poon RT, Fan ST, Wong J. Does diabetes mellitus infuence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma? Am J Gastroenterol 2002;97:1480-1488.
15. No authors listed. Diabetes mellitus. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1985;727: 1-113.
16. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26:S5-20.
17. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR, Gores GJ. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and metaanalysis. Br J Cancer 2009;100:1385-1392.
18. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-2834.
19. Nagasue N, Kohno H, Tachibana M, Yamanoi A, Ohmori H, El-Assal ON. Prognostic factors after hepatic resection for hepatocellular carcinoma associated with Child-Turcotte class B and C cirrhosis. Ann Surg 1999;229:84-90.
20. Egger M, Smith GD. Bias in location and selection of studies. BMJ 1998;316:61-66.
21. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004;22:529-536.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
23. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634.
24. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
25. John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002;8:708-713.
26. Moon JI, Barbeito R, Faradji RN, Gaynor JJ, Tzakis AG. Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: Long-term follow up. Transplantation 2006;82:1625-1628.
27. Xu X, Ling Q, He ZL, Gao F, Zheng SS. Post-transplant diabetes mellitus in liver transplantation: Hangzhou experience. Hepatobiliary Pancreat Dis Int 2008;7:465-470.
28. Huo TI, Lui WY, Huang YH, Chau GY, Wu JC, Lee PC, et al. Diabetes mellitus is a risk factor for hepatic decompensation in patients with hepatocellular carcinoma undergoing resection: a longitudinal study. Am J Gastroenterol 2003;98: 2293-2298.
29. Shirabe K, Shimada M, Gion T, Hasegawa H, Takenaka K, Utsunomiya T, et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg 1999;188:304-309.
30. Huo TI, Wu JC, Huang YH, Chiang JH, Lee PC, Chang FY, et al. Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome. Aliment Pharmacol Ther 2004;19:999-1007.
31. Shimada M, Matsumata T, Akazawa K, Kamakura T, Itasaka H, Sugimachi K, et al. Estimation of risk of major complications after hepatic resection. Am J Surg 1994;167: 399-403.
32. Wang DD, Zhao YM, Wang L, Ren G, Wang F, Xia ZG, et al. Preoperative serum retinol-binding protein 4 is associated with the prognosis of patients with hepatocellular carcinoma after curative resection. J Cancer Res Clin Oncol 2011;137: 651-658.
33. Sumie S, Kawaguchi T, Komuta M, Kuromatsu R, Itano S, Okuda K, et al. Signifcance of glucose intolerance and SHIP2 expression in hepatocellular carcinoma patients with HCV infection. Oncol Rep 2007;18:545-552.
34. Imai K, Takai K, Nishigaki Y, Shimizu S, Naiki T, Hayashi H, et al. Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: A prospective, case series study. Hepatol Res 2010;40:376-382.
35. Yanaga K, Matsumata T, Hayashi H, Shimada M, Urata K, Suehiro T, et al. Effect of diabetes mellitus on hepatic resection. Arch Surg 1993;128:445-448.
36. Shimada M, Takenaka K, Fujiwara Y, Gion T, Shirabe K, Yanaga K, et al. Risk factors linked to postoperative morbidity in patients with hepatocellular carcinoma. Br J Surg 1998;85:195-198.
37. Khan MM, Saito S, Takagi S, Ohnishi H, Izumi H, Sakauchi F, et al. Relationship between hepatocellular carcinoma and impaired glucose tolerance among Japanese. Hepatogastroenterology 2006;53:742-746.
38. Martin JH, Coory MD, Valery PC, Green AC. Association of diabetes with survival among cohorts of Indigenous and non-Indigenous Australians with cancer. Cancer Causes Control 2009;20:355-360.
39. Takamatsu S, Noguchi N, Kudoh A, Nakamura N, Kawamura T, Teramoto K, et al. Infuence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology 2008;55:609-614.
40. Miuma S, Ichikawa T, Taura N, Shibata H, Takeshita S, Akiyama M, et al. The level of fasting serum insulin, but not adiponectin, is associated with the prognosis of early stage hepatocellular carcinoma. Oncol Rep 2009;22:1415-1424.
41. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004;159:1160-1167.
42. Matsumata T, Taketomi A, Kawahara N, Higashi H, Shirabe K, Takenaka K. Morbidity and mortality after hepatic resection in the modern era. Hepatogastroenterology 1995;42:456-460.
43. Shimada M, Hasegawa H, Gion T, Shirabe K, Taguchi K, Takenaka K, et al. Risk factors of the recurrence of hepatocellular carcinoma originating from residual cancer cells after hepatectomy. Hepatogastroenterology 1999;46: 2469-2475.
44. Huo TI, Wu JC, Lui WY, Lee PC, Huang YH, Chau GY, et al. Diabetes mellitus is a recurrence-independent risk factor in patients with hepatitis B virus-related hepatocellular carcinoma undergoing resection. Eur J Gastroenterol Hepatol 2003;15:1203-1208.
45. Ikeda Y, Shimada M, Hasegawa H, Gion T, Kajiyama K, Shirabe K, et al. Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology 1998;27: 1567-1571.
46. Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, et al. Impact of diabetes mellitus on the prognosis of patients with hepatocellular carcinoma. Cancer 2001;91:957-963.
47. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053.
48. Saito K, Inoue S, Saito T, Kiso S, Ito N, Tamura S, et al. Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Gut 2002;51: 100-104.
49. Dellon ES, Shaheen NJ. Diabetes and hepatocellular carcinoma: associations, biologic plausibility, and clinical implications. Gastroenterology 2005;129:1132-1134.
50. Akturk M, Arslan M, Altinova A, Ozdemir A, Ersoy R, Yetkin I, et al. Association of serum levels of IGF-I and IGFBP-1 with renal function in patients with type 2 diabetes mellitus. Growth Horm IGF Res 2007;17:186-193.
51. Lee HC, Tian B, Sedivy JM, Wands JR, Kim M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology 2006; 131:1208-1217.
52. Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A. An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 2004;68:1003-1015.
53. Radcliff K, Tang TB, Lim J, Zhang Z, Abedin M, Demer LL, et al. Insulin-like growth factor-I regulates proliferation and osteoblastic differentiation of calcifying vascular cells via extracellular signal-regulated protein kinase and phosphatidylinositol 3-kinase pathways. Circ Res 2005;96: 398-400.
54. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001;17:189-212.
55. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992;263:H321-326.
56. Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int 2008;28:355-362.
57. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
58. Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 2000;32:3-10.
59. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004;165:1499-1508.
60. Brechot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980;286: 533-535.
61. Wang CC, Hsu CS, Liu CJ, Kao JH, Chen DS. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol 2008;23:779-782.
62. Donadon V, Balbi M, Casarin P, Vario A, Alberti A. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin. World J Gastroenterol 2008;14:5695-5700.
63. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-258.
64. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-1305.